A study to evaluate the efficacy, safety, and tolerability of Olpasiran (AMG890, a small interfering RNA) in subjects with elevated lipoprotein(a).
MAIN RESULTS:
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
N Engl J Med 2022 Nov 17;387(20):1855-1864.
PRESENTATIONS
Reduction of Lipoprotein(a) With Small Interfering RNA – Results of the OCEAN(a)-DOSE (TIMI 67) Trial (O’Donoghue, AHA 2022)
Association of Baseline Lipoprotein(a) and Percentage of Lipoprotein(a) Lowering with Olpasiran (O’Donoghue, ACC 2023)
RNA Inhibition of Lipoprotein(a) with Olpasiran: Effects on Oxidized Phospholipids and Primary Results of the OCEAN(a)-DOSE (TIMI 67) Off-Treatment Extension Period (O’Donoghue, ESC 2023)
OTHER PUBLICATIONS
OCEAN(a)-DOSE on ClinicalTrials.gov
Contact Us about OCEAN(a)-DOSE